Publications Review Article: Dose Optimisation of Infliximab for Acute Severe Ulcerative Colitis Citation Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 Mar;45(5):617-630. doi: 10.1111/apt.13913. Epub 2017 Jan 11. PMID: 28074618; PMCID: PMC6658182. Abstract Background: Although optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen. Tags Antibodies, Colectomy, Drug Therapy, Infliximab, Monoclonal, therapeutic use, Treatment Outcome, Ulcerative Colitis Read More